# Spondyloarthritis, acute anterior uveitis, and Crohn's disease have both shared and distinct gut microbiota

Supplementary Data File



В



#### Supplementary Figure 1: Overview of cohorts and individuals included in this study

A) Flowchart containing numbers of participants at each stage of study with letters denoting reasons for exclusion, namely: *A*=excluded if patient inclusion criteria not met, *B*=excluded if no stool sample given at baseline visit, *C*=excluded if metadata incomplete or sequenced stool sample of poor quality, *D*=excluded if oral antibiotics taken ≤30 days prior to stool sample, or if previous diagnosis of SpA, AAU, CD, UC, or psoriasis present. An asterisk\* denotes that recruitment was still ongoing at the time of analysis. Control samples were obtained from the Optiref study<sup>1</sup> and were resequenced and reprofiled with patient samples. B) Patients were recruited into cohorts reflecting their primary disease pathology, but varied in their expression of human leukocyte antigen (HLA) B27 and their presentation of secondary and tertiary pathologies. CD, Crohn's disease; axSpA, axial spondyloarthritis; AAU, acute anterior uveitis.



**Supplementary Figure 2:** Microbiota composition of immune-mediated disease cohorts and back pain controls. Relative abundances at different taxonomic resolutions of all n=339 individuals in our study, grouped by primary (recruitment) cohort. A) Phylum-level taxonomic profiles. Phyla with a median relative abundance of 0 across at least two cohorts were grouped into "Other". B) Taxonomic profiles of the top six most abundant taxa, corresponding to relative abundances binned at the genus level, except for Lachnospiraceae (representing an unknown genus inside the Lachnospiraceae family). All other taxa were pooled into "Other". Both legends are ranked according to median relative abundance across all cohorts from top to bottom and samples follow the same order in A and B. C) Median relative abundances of phyla by cohort. D) Median relative abundances of genera by cohort. E) Same as C but for enterotype groups determined from the bins in D (modification from Lahti and Shetty<sup>2</sup>, see main text Methods), representing the sum of all ASVs bearing the indicated genus label. F) Same as D, but as in E shown for each enterotype.

All supplementary tables are hosted at <u>www.github.com/sxmorgan/gespic-public</u>, and printed here if space allows.

**Supplementary Table 1: Taxonomic annotations for all n=442 ASVs used in the differential abundance analysis**. Species annotations were inferred using the *dada2::addSpecies()* function with *allowMultiple=F*, in order to exclude identification of ASVs where a species-level consensus was not reached<sup>3</sup>. For the binned differential abundance analysis, the column "bin" was used to sum ASV rows.

Covariate	Variable type	Description
GESPIC	Binary	Any disease diagnosis
Age	Continuous	Age in years
Sex	Binary	Sex assigned at birth
BMI	Continuous	Body mass index
HLAB27	Binary	HLA-B27 expression
CRP	Continuous	C-Reactive Protein in mg/L
ESR	Continuous	Erythrocyte sedimentation rate in mm/h
BASDAI	Ordinal	Bath Ankylosing Spondylitis Disease Activity Index
SpA	Binary	Previous or current spondyloarthritis diagnosis
CD	Binary	Previous or current Crohn's diagnosis
AAU	Binary	Previous or current acute anterior uveitis diagnosis
PsA	Binary	Previous or current psoriatic arthritis diagnosis
Antibiotics_recent	Binary	Antibiotic treatment 2-3 months before sampling
Corticoid_current	Binary	Current glucocorticoid treatment
csDMARD_ever	Binary	Current conventional synthetic DMARD treatment
csDMARD_current	Binary	Previous conventional synthetic DMARD treatment
NSAID_current	Binary	Current NSAID treatment
Smoker	Binary	Current smoker
Cohort_CD	Binary	Crohn's disease cohort (primary CD diagnosis)
Cohort_SpA	Binary	Axial spondyloarthritis cohort (primary SpA diagnosis)
Cohort_AAU	Binary	Acute anterior uveitis cohort (primary AAU diagnosis)
LibSize	Continuous	Raw number of sequencing reads from stool sample

**Supplementary Table 2: Complete list of tested covariates available for all patients and controls** GESPIC: German Spondyloarthritis Inception Cohort; HLA-B27: human leukocyte antigen B27; DMARD: disease-modifying anti-rheumatic drug; NSAID: non-steroidal anti-inflammatory drug

**Supplementary Table 3: Master table of all n=339 anonymized individuals in our study.** ASV and higher taxa (binned at genus- or family-level) relative abundance profiles, alpha diversities, clinical metadata (NA if missing), and serum metabolite concentrations (NA if below limit of detection) are included in wide format.

## Supplementary Methods

#### **Targeted Metabolomic Analysis**

We opted to quantify serum samples because fecal samples are difficult to sample consistently and reflect what is being expelled from the gut, not what the body has access to. In addition, there are standard reference materials (SRMs) that can be used for consistent quality management across batches and studies of serum. A subset of 48 serum samples were selected for tryptophan and SCFA metabolite analysis based on random subsampling within cohorts (n=12 from each of the disease groups plus controls) and using a seed for reproducibility. Relevant constraints were used for each cohort to ensure proportions of key variables observed in the larger dataset were maintained (i.e. HLA-B27 expression, disease activity, and enterotype). One serum sample was mislabeled during sample processing and could not be used for further analysis.

Two quantitative UPLC-MS/MS analyses were carried out independently using dedicated methods that were validated following European Medicines Agency (EMA) guidelines<sup>4</sup>. For each, metabolite extraction was performed followed by injection on a UPLC system 1290 Infinity II (Agilent, Santa Clara, CA, USA) coupled to a TSQ Quantiva (ThermoFisher Scientific, Waltham, MA, USA). For these analyses, commercial standards were spiked and then serially diluted into charcoal single stripped serum (Innovative Research, Novi, MI, USA) to create a calibration curve for quantification, along with solvent blanks and processed blanks. For quality management, Quality Control (QC) samples consisting of pooled samples and charcoal stripped serum samples spiked with a mix of commercial standards at known concentrations (QC standards) were also regularly injected for each batch.

The analysis of SCFA and ketone bodies (n = 11 metabolites in total) followed a previously published method<sup>5</sup>. In a glass vial, 40 µL of sample was incubated for 45 min at 40°C with 20 µL mΜ 3-Nitrophenylhydrazine of 200 hydrochloride. 20 μL of 120 mΜ N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride with 6 % pyridine, and 10  $\mu$ L of Acetonitrile:Water (50:50) (v/v) containing stable isotope labeled internal standards (ISTDs) at 50  $\mu$ M. This was followed by the addition of 410  $\mu$ L of ACN:H<sub>2</sub>O (10:90) (v/v) and centrifugation at 5,500 x g for 20 min at 20° C. The supernatants were then transferred to HPLC vials with inserts for UPLC-MS/MS analysis.

Liquid chromatography used a RP C18 column ACQUITY BEH 1.7  $\mu$ m 2.1x100mm (Waters Corp, Milford, MA, USA) at 40 °C for separation, with H<sub>2</sub>O + 0.1 % (v/v) formic acid (FA) and ACN + 0.1 % (v/v) FA as Phase A and Phase B, respectively. A 0.35 mL min<sup>-1</sup> flow was maintained and the following gradient was used: 5 % B for 5 min, 5-55 % B in 12 min, 100 % B for 1 min, and 2 min 5 % B. Injection volume was 5  $\mu$ L.

The analysis of tryptophan metabolites was carried out according to an in-house developed protocol (Brüning *et al*, in final preparation). Briefly, in an Eppendorf tube,  $50\mu$ L of matrix was extracted with 100  $\mu$ L Methanol:Water (90:10) (v/v) with 0.2% FA and 0.02% ascorbic acid containing ISTDs at 0.15  $\mu$ g/mL. After one-hour incubation at -20°C to allow protein precipitation, the samples were then centrifuged at 12000 rpm for 10 minutes at 10°C. Supernatant was then transferred to HPLC vial inserts for UPLC-MS/MS analysis.

A C18 reverse phase column (Waters XSelect Premier HSS T3 Column, 100Å, 2.5  $\mu$ m, 2.1 X 150 mm) was used at 15°C with the H<sub>2</sub>O + 0.2 % (v/v) FA (Phase A) and Methanol + 0.2 % (v/v) FA (Phase B). The following elution gradient was carried out at 0.4 mL min<sup>-1</sup>: 3% B for 0.45 min, 30% B at 1.2 min, 60% B at 2.7-3.75 min, 95% B at 4.5-6.6 min, 3% B at 6.75-10 min. 5µl were injected per sample.

For both methods, data were then processed with Skyline where metabolite peaks were manually identified and integrated. Area under the curve (AUC) results were exported and processed using the dedicated in-house R package *MetaProc* (paper in preparation). Each analyte was normalized to its respective internal standard, followed by drift correction using the *notame* package<sup>6</sup>, background correction for charcoal stripped serum samples and concentration calculation based on the calibration curve. Precision (RSD <15%) and accuracy (-/+ 15% theoretical concentration) were checked using the QC pools and QC standards. Then, for each measured sample, different statuses were automatically assigned according to calculated Limit of Detection (LOD), Lower and Upper Limits of Quantification (LLOQ, ULOQ, respectively). When the calibration curve fit (R<sup>2</sup>>98%), precision and accuracy did not match previously defined thresholds and/or when the signal was lower than LOD in all samples, the analyte was not further considered.

For subsequent statistical analysis, concentration results were used only when the analyte could be quantified between LLOQ and ULOQ. When the analyte signal was detected between LOD and LLOQ for most samples, only normalized data was retained for relative comparisons. To reveal correlations with host phenotypes and microbial taxa of interest, Wilcoxon or Spearman tests were performed with valid concentration measurements while blocking for relevant covariates using the *coin* R package. Significant associations (q<0.05) between metabolites and the shared phenotype were independent of HLA-B27 status and each of the dichotomous phenotype labels (CD, AAU, SpA).

## References

- 1. Proft, F. *et al.* Comparison of an online self-referral tool with a physician-based referral strategy for early recognition of patients with a high probability of axial spa. *Semin. Arthritis Rheum.* **50**, 1015–1021 (2020).
- 2. Lahti, L. & Al, S. S. et. Dirichlet Multinomial Mixtures. https://microbiome.github.io/tutorials/DMM.html.
- 3. Taxonomic Assignment. https://benjjneb.github.io/dada2/assign.html.
- 4. van Amsterdam, P. *et al.* The European Bioanalysis Forum community's evaluation, interpretation and implementation of the European Medicines Agency guideline on Bioanalytical Method Validation. *Bioanalysis* **5**, 645–659 (2013).
- 5. García-Rivera, M. A., Fernández-Ochoa, Á., Brüning, U., Fritsche-Guenther, R. & Kirwan, J. A. Identification and validation of small molecule analytes in mouse plasma by liquid chromatography-tandem mass spectrometry: A case study of misidentification of a short-chain fatty acid with a ketone body. *Talanta* **242**, 123298 (2022).
- 6. Klåvus, A. *et al.* 'Notame': Workflow for Non-Targeted LC–MS Metabolic Profiling. *Metabolites* **10**, 135 (2020).